Boehringer bets $262M on Arena’s CNS discovery platform

Damian Garde German pharma giant Boehringer Ingelheim is wagering up to $ 262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to spotlight new ...

Obama’s pick for FDA chief clears a Senate panel on the way to likely approval

Damian Garde Robert Califf, a Duke University cardiologist in line to become the next FDA commissioner, won over a Senate panel and is on his way to final confirmation, slated to follow ...

Ysios, J&J back €11.5M round in Aelix to fund trials of HIV treatment

Nick Paul Taylor Aelix Therapeutics has raised €11.5 million ($ 12.6 million) to advance a therapeutic HIV candidate to clinical proof of concept. Ysios Capital, Johnson & ...

U.K. investor Woodford calls again for breakup of ‘complicated’ GSK

Carly Helfand In October, high-profile U.K. fund manager Neil Woodford advocated for a four-way breakup of GlaxoSmithKline, a company he said could unlock "significant shareholder ...

Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, ...

UPDATED: Perrigo recalls store brands of popular Zyrtec, Mucinex meds it makes for CVS, Kroger and others

Eric Palmer Perrigo is having to strip from retailers' shelves hundreds of thousands of packages of its copy of number-one allergy pill Zyrtec that are sold through CVS, Kmart, ...

AbbVie nabs quick FDA review for Viekira Pak in genotype 1b patients

Emily Wasserman AbbVie knows that focusing on untapped niches is key to its hep C success, targeting small populations of patients to increase market share for its blockbuster-in-the-making, ...

Think we’ve seen the last of pharma’s M&A tidal wave? Think again

Carly Helfand If you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're ...

Threshold dumps two-thirds of its staff after a crushing failure

Damian Garde Threshold Pharmaceuticals, whose Merck KGaA-partnered oncology therapy failed in a pair of trials this month, is laying off the majority of its workers and rallying around ...

Sofinnova Partners launches a €300M biotech startup fund with a transatlantic focus

John Carroll PARIS–Sofinnova Partners has reloaded its cash reserves and started to build the next wave of 15 to 20 biotechs for its portfolio. The venture group has wrapped a ...

J&J nabs an early OK for ‘breakthrough’ multiple myeloma blockbuster contender Darzalex

John Carroll Johnson & Johnson scored an early FDA approval for its "breakthrough" blockbuster contender daratumumab, earning a swift OK as a new treatment for multiple ...

Valeant CEO J. Michael Pearson delivers expansion news to Bausch + Lomb employees

Eric Palmer Valeant Pharmaceuticals CEO J. Michael Pearson took a break this week from defending the company's price hike strategies to deliver good news to employees ...
Page 2 of 3412345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS